Predictive biomarker validation in practice: lessons from real trials.
about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewClinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsMammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapiesPrognosis research strategy (PROGRESS) 4: stratified medicine researchStratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkersStrategies for power calculations in predictive biomarker studies in survival dataMulticenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective studyClinical trial designs for testing biomarker-based personalized therapies.The direct assignment option as a modular design component: an example for the setting of two predefined subgroupsEvaluating many treatments and biomarkers in oncology: a new designDesign of clinical trials for biomarker research in oncology.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemGene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.Clinical trial designs incorporating predictive biomarkers.Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials.Drug-diagnostics co-development in oncology.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.PET-CT for radiotherapy treatment planning and response monitoring in solid tumors.Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.Molecular imaging for personalized cancer care.Development and validation of risk models and molecular diagnostics to permit personalized management of cancer.Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women.Current challenges of metastatic breast cancer.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.The development of CHAMP: a checklist for the appraisal of moderators and predictors.Using prognostic factors from case series and cohort studies to identify individuals with poor long-term outcomes during periodontal maintenance.Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.Precision oncology: A new era of cancer clinical trials.Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
P2860
Q26766584-686BF013-B492-4BE8-B6FC-4F040D6045E1Q26795767-2EDF5F50-BD38-43EE-BEEE-F117980559AEQ28074177-E69E48A4-AAFF-409C-97AB-393292926F01Q28709167-30B8FDD9-D6BE-4E3A-A0D5-3BBE0E27314AQ30570744-E0B49397-49B2-4224-AAA5-561E71216702Q31132692-1059C231-CA86-4F6B-8726-4950446D4988Q33921056-3824E602-17A1-49B4-908D-BFD63C6B5EC5Q34113564-52EE91F0-61D6-47A1-848A-81CECD1DC57DQ34977663-077D2C3C-BC89-428A-93B2-4BC2C06E686AQ35026541-35B7B886-94AD-4F97-A3A6-E90306682C0BQ35379179-4B500B7D-6E05-44DD-A2DB-ED28526046C6Q35789708-5E9B17D7-6ACF-4792-BCBB-E6713E07D89DQ35797280-A34272E7-82B6-4469-B0CA-D0E61A9FF7BAQ36055953-4A7D13A5-7D79-4696-BD79-7036CAD91BF1Q36225623-56045974-F71C-4F5D-8192-E225B6D2696FQ36534713-63B4DCBE-5FE7-46EF-93D3-71A75D764D4CQ37238712-7798EBF3-A109-4A0C-88A1-EE36D23AB18FQ37408558-DDC4D41A-1228-44DB-A438-3689083B591BQ37731264-53D45B71-C90B-4ACC-A44D-1A0AA6F9477CQ37832131-E388E3F1-417F-450D-A94F-1E0740D34DBEQ37969774-3E25F012-049C-4A77-9774-D54A5D370029Q37999206-948BCA3C-7271-4551-9562-DD2C07E58E98Q38151510-DAEE6B5F-42D1-44BC-B159-F14969408630Q38450355-4589F7B5-F707-4631-B032-7ED696B90D74Q38785362-9168CA88-544D-4A41-9F45-DAF3E69487E8Q38907580-63C545C0-C20F-47CF-BF5E-B970DF509ACBQ39817075-ECCC0C83-88DA-4BC8-9EDC-D3472F55BA07Q45047946-70691D68-6D5F-4827-A9BA-63B30DFA9B44Q47265229-D56C72E6-4C21-4EA1-8760-22CDE446B722Q47322289-2156FF7E-77AD-4C27-B1C0-2AAC558B0F2DQ48180281-7237E5A5-F606-484B-8028-0EFDEB455B64Q50355746-F39DC9F7-7F44-4C07-A7F2-4E005D17C0ACQ52646483-AB6128EA-D660-4ADA-A52C-EAB74272890D
P2860
Predictive biomarker validation in practice: lessons from real trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Predictive biomarker validation in practice: lessons from real trials.
@ast
Predictive biomarker validation in practice: lessons from real trials.
@en
Predictive biomarker validation in practice: lessons from real trials.
@nl
type
label
Predictive biomarker validation in practice: lessons from real trials.
@ast
Predictive biomarker validation in practice: lessons from real trials.
@en
Predictive biomarker validation in practice: lessons from real trials.
@nl
prefLabel
Predictive biomarker validation in practice: lessons from real trials.
@ast
Predictive biomarker validation in practice: lessons from real trials.
@en
Predictive biomarker validation in practice: lessons from real trials.
@nl
P2860
P356
P1433
P1476
Predictive biomarker validation in practice: lessons from real trials.
@en
P2093
Sumithra J Mandrekar
P2860
P304
P356
10.1177/1740774510368574
P577
2010-04-14T00:00:00Z